NCT05885594View on ClinicalTrials.gov

Imaging Inflammation With Alcohol Use Disorder: an [18F]NOS Study

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

March 15, 2027

Study Completion Date

March 15, 2027

Conditions
Alcohol Use Disorder
Interventions
DRUG

[18F]NOS

\[18F\]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine, also known as \[18F\]NOS, is a positron emitting radiopharmaceutical that has been studied in animals and humans which permits the visualization and measurement by positron emission tomography (PET/CT) imaging of in vivo iNOS expression as a marker of inflammation.

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER